The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2018.01.012
Abstract: Background: Dapagliflozin is a sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitor that reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting glycosuria via inhibiting urinary glucose reabsorption. In addition to improving blood glucose control,… read more here.
Keywords: composite death; trial; declare timi; cardiovascular events ... See more keywords
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0075
Abstract: SOURCE CITATION Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-86. 35762322. read more here.
Keywords: benefit empagliflozin; hospitalization vary; hfpef benefit; death hospitalization ... See more keywords